Press Releases April 16, 2026 07:30 AM

EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

EDAP TMS SA sets May 7, 2026 to announce Q1 2026 financial results and host conference call

By Priya Menon EDAP

EDAP TMS SA, a Nasdaq-listed company specializing in robotic energy-based therapies, announced it will release its first quarter 2026 financial results on May 7, 2026, before market open. The company will hold a conference call and webcast with key executives to discuss the results.

EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026
EDAP

Key Points

  • EDAP TMS SA leads in robotic energy-based medical therapies using ultrasound technology.
  • The company’s flagship product, Focal One, offers minimally invasive prostate focal therapy with potential expansion into other indications.
  • Q1 2026 financial results announcement includes a live webcast and executive discussion.

, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT

AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2026, before market open on Thursday, May 7, 2026.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

Call Details:

Date:                Thursday, May 7th

Time:               8:30 a.m. EDT

Domestic:         1-800-343-4136

International:    1-203-518-9843

Passcode:        EDAP

Webcast:          https://viavid.webcasts.com/starthere.jsp?ei=1759064&tp_key=77ec2128dc

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics, and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and the United States as a leading prostate focal therapy controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.

Investor Contacts
Investor Relations
EDAP TMS SA
[email protected]


Risks

  • Financial performance details are pending, which could lead to volatility post-announcement.
  • Market adoption of robotic energy-based therapies and competitive medical device landscape may impact future growth.
  • Regulatory approvals and reimbursement environments for new medical devices pose ongoing uncertainties.

More from Press Releases

ZOOZ Announces Expected Implementation of 1-for-20 Reverse Share Split May 19, 2026 Golar LNG Limited: 2026 AGM Results Notification May 19, 2026 Aura Announces its 2025 Sustainability Report May 19, 2026 Toll Brothers Reports FY 2026 Second Quarter Results May 19, 2026 Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 May 19, 2026